Atlas Trials

Ruxolitinib Managed Access Program (MAP) for Patients Diagnosed With Severe/Very Severe COVID-19 Illness

Clinical trial NCT04337359 · NO_LONGER_AVAILABLE

Trial details

NCT number
NCT04337359
Sponsor
Novartis Pharmaceuticals
Status
NO_LONGER_AVAILABLE
Study type
EXPANDED_ACCESS
Severe/Very Severe COVID-19 Illness

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.